Highlights Rezolute, Inc.

Equities

RZLT

US76200L3096

Real-time Estimate Cboe BZX Other stock markets 12:10:13 11/05/2024 am IST			5-day change	1st Jan Change
2.995 ^USD	+5.09%		-9.97%	+200.25%

18/04	JonesTrading Starts Rezolute With Buy Rating, $10 Price Target	MT
06/03	Rezolute, Inc. Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Rezolute, Inc. Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia	06/03	CI
Rezolute, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	14/02	CI
Rezolute, Inc. Receives Innovation Passport Designation from the U.K. Innovative Licensing and Access Pathway Steering Group for RZ358 in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism	23/01	CI
Rezolute, Inc. Announces Completion of Enrollment in its RZ402 Phase 2 Study in Diabetic Macular Edema	13/12	CI
Rezolute, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023	14/11	CI
Rezolute Announces Further Evidence of RZ358?s Efficacy in Tumor-Mediated Hyperinsulinism	11/23/11	CI
Rezolute, Inc. Reports Earnings Results for the Full Year Ended June 30, 2023	15/23/15	CI
Rezolute, Inc. Reports Earnings Results for the Fourth Quarter Ended June 30, 2023	15/23/15	CI
Rezolute to Start Late-Stage Study in Congenital Hyperinsulinism in Europe, Other Places	28/23/28	MT
Rezolute, Inc. Provides an Update on Its Clinical Development Plans for RZ358	28/23/28	CI
Rezolute, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023	12/23/12	CI
Rezolute, Inc. Announces KOL Event Highlights Significant Unmet Medical Need in Diabetic Macular Edema	24/23/24	CI
Rezolute, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2022	11/23/11	CI
Rezolute, Inc. Announces Initiation of A Phase 2 Study of Rz402 in Patients with Diabetic Macular Edema	15/22/15	CI
Earnings Flash (RZLT) REZOLUTE Reports Q1 Loss $-0.19	10/22/10	MT
Rezolute, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2022	10/22/10	CI
Rezolute More than Halves Q4 Net Loss	16/22/16	MT
Rezolute, Inc. Reports Earnings Results for the Full Year Ended June 30, 2022	16/22/16	CI
Rezolute, Inc. Reports Earnings Results for the Fourth Quarter Ended June 30, 2022	16/22/16	CI
Rezolute, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2022	13/22/13	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Rezolute, Inc.

Equities

RZLT

US76200L3096

Highlights

Filters